Cargando…

Procalcitonin and mortality in status epilepticus: an observational cohort study

INTRODUCTION: Acute-phase proteins, such as procalcitonin (PCT), C-reactive protein (CRP) and albumin, may relate with course and outcome in status epilepticus (SE), as seizures bring about inflammation, changes of cytokine levels and blood–brain barrier breakdown. We aimed to determine the predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutter, Raoul, Valença, Martina, Tschudin-Sutter, Sarah, Rüegg, Stephan, Marsch, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598971/
https://www.ncbi.nlm.nih.gov/pubmed/26450065
http://dx.doi.org/10.1186/s13054-015-1072-9
_version_ 1782394165378678784
author Sutter, Raoul
Valença, Martina
Tschudin-Sutter, Sarah
Rüegg, Stephan
Marsch, Stephan
author_facet Sutter, Raoul
Valença, Martina
Tschudin-Sutter, Sarah
Rüegg, Stephan
Marsch, Stephan
author_sort Sutter, Raoul
collection PubMed
description INTRODUCTION: Acute-phase proteins, such as procalcitonin (PCT), C-reactive protein (CRP) and albumin, may relate with course and outcome in status epilepticus (SE), as seizures bring about inflammation, changes of cytokine levels and blood–brain barrier breakdown. We aimed to determine the predictive value of serum levels of PCT at SE onset for the emergence of infections and unfavorable outcome in adult patients with SE. Furthermore, we sought to compare the predictive value of PCT, CRP and albumin for death. METHODS: This observational cohort study was performed in the intensive care units of the University Hospital Basel (Switzerland), a university-affiliated tertiary care center. Adult patients with SE admitted from 2005 to 2012 were included. Serum levels of PCT, CRP and albumin were assessed at SE onset. Unfavorable outcome (i.e., death and a Glasgow Outcome Score of 1 to 3) during hospital stay and mortality after 30 days were considered the primary and infections as the secondary outcome measures. RESULTS: In 91 SE patients, mortality was 23.1 % during hospital stay and at 30-days follow-up. Infections emerged in 30.8 % of patients. In the multivariable analysis, PCT predicted unfavorable outcome independently from possible confounders such as acute etiology, infections during SE, the Charlson Comorbidity Index, and the Status Epilepticus Severity Score (hazard ratio 1.44 per every increasing ug/L, 95 % confidence interval 1.11-1.87). Additional multivariable analysis including serum levels of PCT, CRP and albumin revealed PCT as the only biomarker independently associated with an increased hazard for unfavorable outcome. PCT levels at SE onset were not related to infections during SE. CONCLUSIONS: Serum PCT levels measured at SE onset are independently associated with unfavorable outcome but do not predict the emergence of infections during SE. Procalcitonin may increase the predictive value of clinical scoring systems allowing for rapid risk stratification early in the course of SE.
format Online
Article
Text
id pubmed-4598971
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45989712015-10-09 Procalcitonin and mortality in status epilepticus: an observational cohort study Sutter, Raoul Valença, Martina Tschudin-Sutter, Sarah Rüegg, Stephan Marsch, Stephan Crit Care Research INTRODUCTION: Acute-phase proteins, such as procalcitonin (PCT), C-reactive protein (CRP) and albumin, may relate with course and outcome in status epilepticus (SE), as seizures bring about inflammation, changes of cytokine levels and blood–brain barrier breakdown. We aimed to determine the predictive value of serum levels of PCT at SE onset for the emergence of infections and unfavorable outcome in adult patients with SE. Furthermore, we sought to compare the predictive value of PCT, CRP and albumin for death. METHODS: This observational cohort study was performed in the intensive care units of the University Hospital Basel (Switzerland), a university-affiliated tertiary care center. Adult patients with SE admitted from 2005 to 2012 were included. Serum levels of PCT, CRP and albumin were assessed at SE onset. Unfavorable outcome (i.e., death and a Glasgow Outcome Score of 1 to 3) during hospital stay and mortality after 30 days were considered the primary and infections as the secondary outcome measures. RESULTS: In 91 SE patients, mortality was 23.1 % during hospital stay and at 30-days follow-up. Infections emerged in 30.8 % of patients. In the multivariable analysis, PCT predicted unfavorable outcome independently from possible confounders such as acute etiology, infections during SE, the Charlson Comorbidity Index, and the Status Epilepticus Severity Score (hazard ratio 1.44 per every increasing ug/L, 95 % confidence interval 1.11-1.87). Additional multivariable analysis including serum levels of PCT, CRP and albumin revealed PCT as the only biomarker independently associated with an increased hazard for unfavorable outcome. PCT levels at SE onset were not related to infections during SE. CONCLUSIONS: Serum PCT levels measured at SE onset are independently associated with unfavorable outcome but do not predict the emergence of infections during SE. Procalcitonin may increase the predictive value of clinical scoring systems allowing for rapid risk stratification early in the course of SE. BioMed Central 2015-10-09 2015 /pmc/articles/PMC4598971/ /pubmed/26450065 http://dx.doi.org/10.1186/s13054-015-1072-9 Text en © Sutter et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sutter, Raoul
Valença, Martina
Tschudin-Sutter, Sarah
Rüegg, Stephan
Marsch, Stephan
Procalcitonin and mortality in status epilepticus: an observational cohort study
title Procalcitonin and mortality in status epilepticus: an observational cohort study
title_full Procalcitonin and mortality in status epilepticus: an observational cohort study
title_fullStr Procalcitonin and mortality in status epilepticus: an observational cohort study
title_full_unstemmed Procalcitonin and mortality in status epilepticus: an observational cohort study
title_short Procalcitonin and mortality in status epilepticus: an observational cohort study
title_sort procalcitonin and mortality in status epilepticus: an observational cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598971/
https://www.ncbi.nlm.nih.gov/pubmed/26450065
http://dx.doi.org/10.1186/s13054-015-1072-9
work_keys_str_mv AT sutterraoul procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy
AT valencamartina procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy
AT tschudinsuttersarah procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy
AT rueggstephan procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy
AT marschstephan procalcitoninandmortalityinstatusepilepticusanobservationalcohortstudy